Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934610 | 0.76 | — | — | |
| SCHEMBL27915791 | 0.74 | — | — | |
| SCHEMBL5273019 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL11159957 | 0.74 | CYP2D6 (0.40) | CYP2D6CYP2C19KDM4CSMN1; SMN2 | |
| SCHEMBL25353226 | 0.72 | CYP2D6 (0.39) | CYP2D6CYP2C19KDM4CEPHX1SMN1; SMN2 | |
| SCHEMBL6729569 | 0.72 | — | — | |
| SCHEMBL9800469 | 0.72 | — | — | |
| SCHEMBL3956441 | 0.72 | — | — | |
| SCHEMBL2040611 | 0.72 | — | — | |
| SCHEMBL16480859 | 0.72 | CYP2D6 (0.39) | CYP2D6CYP2C19KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | CYP2D6 710/4885CYP2C19 449/4885KDM4C 1594/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | CYP2D6 745/4885CYP2C19 484/4885KDM4C 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.